Author

C. A. Klebanoff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 4 Approach:experimental assay· 4 Research Focus:cell-cell communication· 2 Approach:deep learning· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

D. A. Scheinberg· 2 shared M. G. Klatt· 2 shared S. S. Chandran· 2 shared A. Barpanda· 1 shared A. Chow· 1 shared A. Diaz· 1 shared A. Dobrin· 1 shared A. Drilon· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. A. Scheinberg

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

D. W. Kwok, N. O. Stevers, T. Nejo, L. H. Chen, I. Etxeberria, J. Jung, K. Okada, M. Colton Cove, S. Lakshmanachetty, M. Gallus, A. Barpanda, C. Hong, G. K. L. Chan, S. H. Wu, E. Ramos, , H. Okada

The paper identifies tumor-wide splicing aberrations that generate public neoantigens, enabling T-cell-based immunotherapies targeting intratumoral heterogeneity.

bioRxiv · Oct 19, 2023 · PreprintCancer Biology

The resting and ligand-bound states of the membrane-embedded human T-cell receptor-CD3 complex

R. Q. Notti, F. Yi, S. Heissel, M. W. Bush, Z. Molvi, P. Das, H. Molina, C. A. Klebanoff, T. Walz

This study presents cryo-EM structures of the human TCR-CD3 complex in its resting and ligand-bound states, revealing conformational changes and the importance of native lipid environments.

bioRxiv · Aug 22, 2023Biochemistry

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

A. Chow, F. Z. Uddin, L. Mangarin, H. Rizvi, A. Dobrin, S. E. Tischfield, A. Quintanal-Villalonga, J. M. Chan, N. S. Shah, V. Allaj, P. Manoj, M. Mattar, M. Meneses, M. Liu, R. Landau, , C. M. Rudin

This study identifies CD39 as a marker for tumor-reactive CD8 T cells in lung cancer, showing its association with clinical outcomes and response to immune checkpoint therapy.

bioRxiv · Jan 24, 2022 · PreprintImmunology

Genetic editing of CISH enhances T cell effector programs independently of immune checkpoint cell surface ligand expression

E. Arthofer, K. Chakraborty, L. Viney, M. J. Johnson, B. R. Webber, B. S. Moriarity, E. Lou, M. Choudhry, C. A. Klebanoff, T. Henley

This study shows that genetic editing of CISH enhances T cell anti-tumor activity independently of PD-L1 expression, outperforming PD-1 and TIGIT disruption in certain contexts.

bioRxiv · Aug 17, 2021 · PreprintCancer Biology

Immunogenicity of a public neoantigen derived from mutated PIK3CA

S. S. Chandran, J. Ma, M. G. Klatt, F. Dundar, C. Bandlamudi, P. C. Razavi, H. Y. Wen, B. Weigelt, P. Zumbo, S. N. Fu, L. B. Banks, W. D. Bestman, A. Drilon, D. Betel, D. A. Scheinberg, , C. A. Klebanoff

The paper investigates the immunogenicity of a public neoantigen derived from mutated PIK3CA, showing it is recognized by T cells and presents a framework for immunotherapy.

bioRxiv · Apr 8, 2021 · PreprintImmunology

Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform

R. S. Gejman, H. F. Jones, M. G. Klatt, A. Y. Chang, C. Y. Oh, S. S. Chandran, T. Korontsvit, V. Zakahleva, T. Dao, C. A. Klebanoff, D. A. Scheinberg

This study introduces a high-throughput genetic platform to identify on- and off-targets of T cell receptor therapeutic agents using MHC-I ligands.

bioRxiv · Sep 1, 2019Cancer Biology